HUMACYTE INC (NASDAQ: HUMA)

HUMACYTE INC

NASDAQ: HUMA (Humacyte, Inc.)

Last update: 2 days ago, 9:25PM

5.10

-0.08 (-1.54%)

Add to watchlist

Previous Close	5.18
Open	5.13
Volume	3,189,547
Avg. Volume (3M)	4,740,867
Market Cap	656,206,784

Price / Book

30.28

52 Weeks Range	2.48 (-51%) — 9.97 (95%)
Earnings Date	20 Mar 2025 - 24 Mar 2025

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Mixed	Mixed
	Biotechnology (Global)	Mixed	Mixed
Stock	Humacyte, Inc.	Bullish	Bullish

AIStockmoo Score

1.5

Analyst Consensus	5.0
Insider Activity	NA
Price Volatility	-2.0
Technical Moving Averages	1.0
Technical Oscillators	2.0
Average	1.50

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
HUMA	656 M	-	-	30.28
CYTK	6 B	-	-	60.31
ARWR	2 B	-	-	13.19
FTRE	2 B	-	-	1.14
REPL	971 M	-	-	2.24
ABUS	648 M	-	-	5.83

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Sector	Healthcare
Industry	Biotechnology
Investment Style	Small Value
% Held by Insiders	26.87%
% Held by Institutions	30.02%

Ownership

Name	Date	Shares Held
Monashee Investment Management Llc	30 Sep 2024	535,000

52 Weeks Range	2.48 (-51%) — 9.97 (95%)
Price Target Range	10.00 (96%) — 25.00 (390%)
High	25.00 (D. Boral Capital, 390.20%)	Buy
	25.00 (EF Hutton, 390.20%)	Buy
Median	16.00 (213.73%)
Low	10.00 (TD Cowen, 96.08%)	Buy
	10.00 (BTIG, 96.08%)	Buy
Average	17.00 (233.33%)
Total	6 Buy
Avg. Price @ Call	4.90

Firm	Date	Target Price	Call	Price @ Call
Benchmark	23 Dec 2024	17.00 (233.33%)	Buy	4.65
Benchmark	10 Oct 2024	15.00 (194.12%)	Buy	5.55
D. Boral Capital	20 Dec 2024	25.00 (390.20%)	Buy	4.64
D. Boral Capital	21 Nov 2024	25.00 (390.20%)	Buy	4.38
HC Wainwright & Co.	20 Dec 2024	15.00 (194.12%)	Buy	4.64
HC Wainwright & Co.	18 Nov 2024	12.00 (135.29%)	Buy	4.45
EF Hutton	28 Oct 2024	25.00 (390.20%)	Buy	5.42
BTIG	18 Oct 2024	10.00 (96.08%)	Buy	5.03
TD Cowen	18 Oct 2024	10.00 (96.08%)	Buy	5.03

No data within this time range.

Date	Type	Details
19 Dec 2024	Announcement	Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
02 Dec 2024	Announcement	Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
23 Nov 2024	Announcement	HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025
22 Nov 2024	Announcement	Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
22 Nov 2024	Announcement	HUMACYTE DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on January 17, 2025
21 Nov 2024	Announcement	Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
21 Nov 2024	Announcement	Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
21 Nov 2024	Announcement	HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
20 Nov 2024	Announcement	Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
19 Nov 2024	Announcement	Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
18 Nov 2024	Announcement	Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
14 Nov 2024	Announcement	Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
08 Nov 2024	Announcement	Humacyte Third Quarter 2024 Financial Results and Business Update
06 Nov 2024	Announcement	Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
28 Oct 2024	Announcement	Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
23 Oct 2024	Announcement	Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
22 Oct 2024	Announcement	Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
21 Oct 2024	Announcement	Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
19 Oct 2024	Announcement	Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
08 Oct 2024	Announcement	Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Total Debt/Equity (MRQ)	71.00%
Current Ratio (MRQ)	1.10
Operating Cash Flow (TTM)	-90.60 M
Levered Free Cash Flow (TTM)	-58.33 M

Return on Assets (TTM)	-53.23%
Return on Equity (TTM)	-850.81%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)